title: Premature Infants 750-1,250 g Birth Weight Supplemented with a Novel Human Milk-Derived Cream Are Discharged Sooner.
abstract: OBJECTIVE
  Infants may benefit from early nutritional intervention to decrease hospital stay. To evaluate the effects of adding a human milk (HM)-derived cream (Cream) product to a standard feeding regimen in preterm infants.
  
  
  METHODS
  In a prospective multicenter randomized study, infants with birth weights 750-1,250 g were assigned to a Control or Cream group. The Control group received a standard feeding regimen consisting of mother's own milk or donor HM with donor HM-derived fortifier. The Cream group received the standard feeding regimen along with an additional HM-derived cream supplement when the HM they received was <20 kcal/oz. Primary outcomes of this secondary analysis included comorbidities, length of stay (LOS), and postmenstrual age (PMA) at discharge.
  
  
  RESULTS
  We enrolled 75 infants (Control n = 37, Cream n = 38) with gestational age 27.7 ± 1.8 weeks and birth weight 973 ± 145 g (mean ± SD). After adjusting for gestational age, birth weight, and presence of bronchopulmonary dysplasia (BPD), the Cream group had a decreased PMA at discharge (39.9 ± 4.8 versus 38.2 ± 2.7 weeks, p = 0.03) and LOS (86 ± 39 versus 74 ± 22 days, p = 0.05). For 21 infants with BPD, these values trended toward significance for PMA at discharge (44.2 ± 6.1 versus 41.3 ± 2.7 weeks, p = 0.08) and LOS (121 ± 49 versus 104 ± 23 days, p = 0.08).
  
  
  CONCLUSIONS
  Very preterm infants who received an HM-derived cream supplement were discharged earlier. Infants with BPD may have benefited the most.
authors.affiliation: 1 Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital , Houston, Texas.
authors.forename: Amy B
authors.initials: AB
authors.lastname: Hair
authors.affiliation: 1 Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital , Houston, Texas.
authors.forename: Erynn M
authors.initials: EM
authors.lastname: Bergner
authors.affiliation: 2 Prolacta Bioscience , Industry, California.
authors.forename: Martin L
authors.initials: ML
authors.lastname: Lee
authors.affiliation: 3 Department of Pediatrics, University of Texas Health Science Center , San Antonio, Texas.
authors.forename: Alvaro G
authors.initials: AG
authors.lastname: Moreira
authors.affiliation: 4 Department of Pediatrics, Dell Medical School at the University of Texas at Austin , Austin, Texas.
authors.forename: Keli M
authors.initials: KM
authors.lastname: Hawthorne
authors.affiliation: 2 Prolacta Bioscience , Industry, California.
authors.forename: David J
authors.initials: DJ
authors.lastname: Rechtman
authors.affiliation: 4 Department of Pediatrics, Dell Medical School at the University of Texas at Austin , Austin, Texas.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Abrams
authors.affiliation: 3 Department of Pediatrics, University of Texas Health Science Center , San Antonio, Texas.
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Blanco
mesh_terms: D001997:Bronchopulmonary Dysplasia; D002657:Child Development; D019587:Dietary Supplements; D005260:Female; D005527:Food, Fortified; D005865:Gestational Age; D006801:Humans; D007223:Infant; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007902:Length of Stay; D016014:Linear Models; D008297:Male; D008895:Milk, Human; D015999:Multivariate Analysis; D011446:Prospective Studies